Glenmark Life Sciences Ltd

Alivus Life Sciences Ltd has announced the closure of its trading window from October 1, 2026, to October 31, 2026, inclusive. This closure is in preparation for the Board of Directors' meeting scheduled for October 29, 2026. The primary agenda for this meeting is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. The company has informed its designated persons about this trading window restriction as per SEBI regulations.

Alivus Life Sciences Ltd has announced that its Board of Directors will convene on October 29, 2026. The primary agenda item is to consider and approve the unaudited financial results for the quarter and half-year ended September 30, 2026. In line with SEBI regulations on insider trading, the company has also declared a trading window closure for designated persons from October 1, 2026, to October 31, 2026, to prevent potential misuse of information related to the financial results.

Alivus Life Sciences Ltd has received an order from the Central Goods & Service Tax Department for FY 2020-21 and FY 2021-22. The order involves a demand of ₹25,61,400 (₹25.61 Lakhs) along with a penalty of ₹25,61,400 (₹25.61 Lakhs) and applicable interest. The total amount involved is ₹51,22,800 (₹51.23 Lakhs). The company stated that there is no material impact on its financial, operational, or other activities. Alivus Life Sciences is currently assessing its right to appeal the order.

Alivus Life Sciences Ltd has acquired a 9.21% stake in Torrent Urja 19 Private Limited for ₹14.04 Crores. This investment is part of Alivus's commitment to achieve carbon neutrality by 2030 and comply with regulatory requirements for captive power users under Indian electricity laws. Torrent Urja 19 Private Limited is a special purpose vehicle focused on setting up solar and other renewable energy projects. The acquisition does not fall under related party transactions, although Alivus's promoter, Nirma Limited, also holds a stake in the SPV.

Alivus Life Sciences Ltd has announced the incorporation of its wholly owned subsidiary, Alivus Life Sciences Do Brasil Ltda., in Sao Paulo, Brazil, on September 15, 2026. The subsidiary has an authorized capital of R$ 500,000.00. This move is a strategic expansion into the Brazilian market within the pharmaceuticals industry. The incorporation was approved by the Federative Republic of Brazil National Registrar of Legal Entities. The company will subscribe to 100% of the subsidiary's share capital, amounting to R$ 500,000.00, which is considered a cash consideration and not a related party transaction.

Alivus Life Sciences Limited has announced the acquisition of a 76% majority stake in IQGenX Pharma Private Limited for a consideration of INR 91.2 million. IQGenX, a custom research organization founded in 2016, specializes in formulation development for oral solids, sterile injectables, and ophthalmic solutions across regulated and semi-regulated markets. This acquisition aims to integrate Alivus's API expertise with IQGenX's formulation capabilities, creating an end-to-end platform for complex drug delivery formats. The move is expected to expand Alivus's global customer base, enhance its CDMO services, and focus on niche oncology assets for out-licensing. The deal is subject to customary closing conditions and is anticipated to conclude by the end of the current calendar year.

Alivus Life Sciences Limited announced its Board of Directors has approved the acquisition of a 76% stake in IQGEN-X Pharma Private Limited for an aggregate consideration of approximately ₹9.12 crores. The acquisition aims to expand Alivus's offerings in the API and CDMO space by integrating IQGEN-X Pharma's formulation development capabilities for oral solids, sterile injectables, and ophthalmic solutions. The transaction is expected to be completed by December 6, 2026, subject to customary closing conditions. IQGEN-X Pharma reported a turnover of INR 348 Lacs for the financial year ended March 31, 2026. This acquisition is not considered a related party transaction.

Alivus Life Sciences Ltd (formerly Glenmark Life Sciences Ltd) has submitted its Integrated Annual Report for the Financial Year 2025-26, in compliance with SEBI LODR Regulations. The report, prepared according to the Integrated Reporting Framework and GRI standards, offers a holistic view of the company's strategy, governance, performance, and outlook, emphasizing value creation across six capitals: Financial, Manufactured, Intellectual, Human, Social & Relationship, and Natural. The report covers both financial and non-financial performance from April 1, 2025, to March 31, 2026. Alivus is leveraging its expertise in chemistry and manufacturing to expand into adjacent business areas, aiming to enhance its portfolio and customer relationships. The company has obtained independent assurance for its BRSR Core KPIs from BSI.

Alivus Life Sciences Ltd has announced its 15th Annual General Meeting (AGM) to be held on Tuesday, September 8, 2026, at 3:00 p.m. IST via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). The meeting will cover ordinary business including the adoption of audited financial statements for FY26, declaration of a final dividend of ₹5 per equity share, and the re-appointment of Mr. Hiren Patel as a Director. Special business includes ratifying the remuneration for Cost Auditors, Kirit Mehta & Co. LLP, for FY27. Shareholders can exercise their voting rights through e-voting from September 4 to September 7, 2026. The cut-off date for e-voting eligibility is September 1, 2026.

Alivus Life Sciences Ltd has announced Tuesday, September 1, 2026, as the record date for determining shareholder entitlement to a final dividend of ₹5.00 per equity share. This dividend is for the financial year ended March 31, 2026, and was recommended by the Board of Directors on May 14, 2026. Shareholders will receive the dividend, subject to tax deduction, on or after Friday, September 11, 2026, provided it is approved at the upcoming Fifteenth Annual General Meeting (AGM) scheduled for Tuesday, September 8, 2026. The AGM will be conducted via Video Conferencing or Other Audio-Visual Means.